Hsbc Holdings PLC Purchases 30,671 Shares of CryoPort, Inc. $CYRX

Hsbc Holdings PLC boosted its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 96.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,405 shares of the company's stock after buying an additional 30,671 shares during the period. Hsbc Holdings PLC owned approximately 0.12% of CryoPort worth $419,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of CYRX. Point72 Asia Singapore Pte. Ltd. raised its holdings in CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at about $51,000. SBI Securities Co. Ltd. raised its holdings in shares of CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after purchasing an additional 10,975 shares during the last quarter. CWM LLC increased its holdings in CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after buying an additional 10,591 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in CryoPort by 4,434.6% during the first quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock worth $89,000 after buying an additional 14,235 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

CryoPort Price Performance

CryoPort stock traded up $1.50 during mid-day trading on Friday, hitting $10.35. 1,057,323 shares of the company traded hands, compared to its average volume of 560,718. CryoPort, Inc. has a one year low of $4.58 and a one year high of $10.39. The stock has a market cap of $518.19 million, a price-to-earnings ratio of 7.78 and a beta of 1.62. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The stock has a fifty day moving average price of $8.03 and a 200-day moving average price of $6.79.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. On average, equities analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on CYRX shares. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th. Stephens began coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price target on the stock. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a research note on Wednesday, August 6th. BTIG Research reduced their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, July 7th. Finally, Leerink Partners raised shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective for the company in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $12.00.

Insider Transactions at CryoPort

In related news, CFO Robert Stefanovich sold 9,300 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the sale, the chief financial officer directly owned 207,213 shares in the company, valued at $1,796,536.71. This represents a 4.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jerrell Shelton sold 16,344 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.06, for a total transaction of $115,388.64. Following the sale, the chief executive officer owned 912,419 shares of the company's stock, valued at $6,441,678.14. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 492,247 shares of company stock worth $3,384,579. Corporate insiders own 10.00% of the company's stock.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.